These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 8677449

  • 1. Ifosfamide in the treatment of ovarian cancer.
    Markman M.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):47-9. PubMed ID: 8677449
    [Abstract] [Full Text] [Related]

  • 2. New options for the treatment of advanced ovarian cancer.
    Dunton CJ.
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
    Markman M.
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438
    [Abstract] [Full Text] [Related]

  • 5. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Jun; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 6. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Jun; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 7. Ifosfamide in the treatment of germ cell tumors.
    Nichols CR.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):65-73. PubMed ID: 8677452
    [Abstract] [Full Text] [Related]

  • 8. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY, Barnes MN, Niwas S, Robertson MW, Alvarez R, Austin JM, Kilgore LC, Partridge EE.
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [Abstract] [Full Text] [Related]

  • 9. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Pöch G, Indefrei D, Mallmann P, Andreotti PE.
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [Abstract] [Full Text] [Related]

  • 10. Paclitaxel in salvage therapy for germ cell tumors.
    Motzer RJ.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
    [Abstract] [Full Text] [Related]

  • 11. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [Abstract] [Full Text] [Related]

  • 12. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A, Lück HJ, Meerpohl HG.
    Zentralbl Gynakol; 1997 Oct; 119(7):299-323. PubMed ID: 9340970
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 16. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH.
    Minerva Ginecol; 2004 Feb 15; 56(1):81-9. PubMed ID: 14973412
    [Abstract] [Full Text] [Related]

  • 17. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A.
    Semin Oncol; 2000 Feb 15; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [Abstract] [Full Text] [Related]

  • 18. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 19. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
    Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, Mosseri V, Palangié T, Scholl S, Sastre X, Pouillart P.
    J Infus Chemother; 1996 Oct 15; 6(1):47-9. PubMed ID: 8748008
    [Abstract] [Full Text] [Related]

  • 20. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.